Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03536949
Other study ID # RVL-1201-203
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 20, 2018
Est. completion date March 27, 2019

Study information

Verified date September 2020
Source RVL Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.


Recruitment information / eligibility

Status Completed
Enrollment 234
Est. completion date March 27, 2019
Est. primary completion date March 14, 2019
Accepts healthy volunteers No
Gender All
Age group 9 Years and older
Eligibility Inclusion Criteria:

1. Male or Female 9 years of age or older

2. Females must not be pregnant or planning to get pregnant and must use acceptable form of contraception

3. Must be able to self-administer study medication

4. Must be able to understand and sign an Informed Consent Form (ICF). For minor subjects, the subject's parent or legal guardian must provide permission by signing an ICF on behalf of the subject and the subject should provide assent.

Exclusion Criteria:

1. Congenital ptosis

2. Horner syndrome

3. Myasthenia gravis

4. Mechanical ptosis

5. Previous ptosis surgery

6. Resting heart rate outside the normal range

7. Hypertension with resting diastolic blood pressure

8. Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RVL-1201
RVL-1201 ophthalmic solution, 0.1%
Other:
Vehicle ophthalmic solution
Vehicle placebo ophthalmic solution

Locations

Country Name City State
United States Drs. Quinn, Foster & Associates Athens Ohio
United States Round Rock Eye Consultants Austin Texas
United States Texan Eye / Keystone Research, Ltd. Austin Texas
United States Hernando Eye Institute Brooksville Florida
United States CEENTA Charlotte North Carolina
United States Apex Eye Cincinnati Ohio
United States Apex Eye Cincinnati Ohio
United States Abrams Eye Center Cleveland Ohio
United States Danbury Eye Physicians and Surgeons Danbury Connecticut
United States Orange County Ophthalmology Medical Group Garden Grove California
United States Seidenberg Protzko Eye Associates Havre De Grace Maryland
United States Cornerstone Eye Care High Point North Carolina
United States Silverstein Eye Centers Kansas City Missouri
United States Lake Travis Eye and Laser Center Lakeway Texas
United States Shettle Eye Research Largo Florida
United States West Coast Eye Institute Lecanto Florida
United States Sabal Eye Care Longwood Florida
United States Maitland Vision Center Maitland Florida
United States North Valley Eye Medical Mission Hills California
United States Nashville Vision Associates Nashville Tennessee
United States Eye Research Foundation Newport Beach California
United States Mississippi Eye Associates Ocean Springs Mississippi
United States Pendelton Eye Center Oceanside California
United States North Bay Eye Associates Petaluma California
United States Barnet, Dulany Perkins Phoenix Arizona
United States Kennar Eye Care Pittsburg Kansas
United States Rochester Ophthalmological Group Rochester New York
United States Coastal Research Associates Roswell Georgia
United States R & R Research San Antonio Texas
United States Sarasota Retina Institute Sarasota Florida
United States Heart of America Eye Care Shawnee Mission Kansas
United States East Florida Eye Institute Stuart Florida
United States South Shore Eye Care Wantagh New York
United States Comprehensive Eye Care Washington Missouri
United States Michael K. Tran, MD Inc. Westminster California

Sponsors (1)

Lead Sponsor Collaborator
RVL Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 Intraocular pressure will be measured in mmHg utilizing a tonometer and using the standard of care. If possible, the same calibrated instrument should be used for a given subject throughout the study. Screening/Day 1 to Day 84
Primary Mean Change From Baseline in Pupil Diameter (PD) at Day 84 Pupil diameter will be measured in millimeters (either horizontally or vertically if top of pupil is not visible in photograph) from the external photograph. Screening/Day 1 to Day 84
See also
  Status Clinical Trial Phase
Completed NCT00864656 - Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine N/A
Recruiting NCT02959697 - Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair N/A
Recruiting NCT02501187 - Risk of Dry Eye Post Different Surgeries for Blepharoptosis Repair N/A
Completed NCT00793988 - Vibration-Assisted Anaesthesia Phase 4
Completed NCT02367677 - Digital Photographs to Evaluate Blepharoptosis N/A
Recruiting NCT01239498 - Saline Injection - Assisted Anesthesia in Eyelid Surgery Phase 4
Not yet recruiting NCT05358977 - Fibrin Sealant in Eyelid Surgery Phase 2/Phase 3
Completed NCT01848041 - Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis Phase 1/Phase 2
Completed NCT01350024 - Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid N/A
Completed NCT06047418 - Blepharoptosis in Indonesia: A 5-Year Multicenter Study on Characteristics and Surgical Evaluation
Active, not recruiting NCT03149367 - Surgical Management of Blepharoptosis N/A
Completed NCT03565887 - Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis Phase 3
Recruiting NCT01968174 - Astigmatic Changes Secondary to Eyelid Surgeries N/A
Active, not recruiting NCT04678115 - Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis N/A
Not yet recruiting NCT04235803 - Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery N/A
Completed NCT02988856 - Magnetic Correction of Eye Lid Paralysis N/A
Terminated NCT03239418 - NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy N/A
Not yet recruiting NCT02638610 - Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries N/A
Enrolling by invitation NCT05945615 - Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Phase 3
Recruiting NCT06292182 - Red Light Ptosis Proof-of-Concept N/A